Century Health to Create Steatotic Liver Disease Database

Why It Matters

By aggregating large‑scale, AI‑curated liver disease data, researchers can uncover progression patterns and therapeutic targets faster, accelerating drug pipelines and improving patient care in a growing metabolic disease market.

Key Takeaways

• AI platform extracts structured and unstructured EHR data
• Database will cover tens of thousands of steatotic liver records
• Focus initially on fibrosis, biomarkers, alcohol exposure patterns
• Supports translational research and drug development pipelines
• Century Health raised $2 million pre‑seed in 2024

Pulse Analysis

The rise of metabolic dysfunction‑associated steatotic liver disease (MASLD) has created a pressing need for robust, real‑world evidence. Traditional clinical trials capture limited snapshots, while electronic health records hold longitudinal insights across diverse populations. Century Health’s AI engine can parse both structured fields and narrative notes, transforming raw EHR data into analyzable cohorts. This capability not only accelerates hypothesis generation but also reduces the time and cost associated with building disease registries from scratch.

Beyond data extraction, the partnership with VCU adds academic rigor and institutional oversight, ensuring data quality and compliance. By initially targeting fibrosis staging, non‑invasive biomarkers, and alcohol exposure patterns, the database addresses the most clinically actionable variables. Researchers will be able to model disease trajectories, identify high‑risk subpopulations, and evaluate real‑world treatment effectiveness. Such granular insights are critical for pharmaceutical companies seeking to design targeted trials and for clinicians aiming to personalize therapy.

Century Health’s broader alliance strategy—spanning renal, respiratory, and neurocognitive diseases—signals a market trend toward AI‑driven, cross‑disciplinary data platforms. The $2 million pre‑seed funding underscores investor confidence in the commercial potential of real‑world evidence as a drug development catalyst. As regulatory bodies increasingly accept RWE for labeling decisions, databases like the one being built for steatotic liver disease could become indispensable assets, shaping both scientific discovery and commercial outcomes.